Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

References

• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 2006;20:104–18
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64:580–8
   PubMed Web of Science ®Google Scholar
• Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenia patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotics drugs. BMC Med 2005;3:21
   Google Scholar
• Ascher-Svanum H, Chen L, Jamal HH, et al. Symptom worsening associated with treatment discontinuation in schizophrenia trials. Schizophr Res 2006;81(Suppl):75
   Google Scholar
• Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006;9:77–89
   PubMed Web of Science ®Google Scholar
• Dossenbach MR, Kratky P, Schneidman M, et al. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 2001;62(Suppl 2):28–34
   PubMed Web of Science ®Google Scholar
• Park S, Ross-Degnan D, Adams AS, et al. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br J Psychiatry 2005;187:137–42
   PubMed Web of Science ®Google Scholar
• Meyer JM, Pandina G, Bossie CA, et al. Effects of switching from olanzapine to risperidone on the prevalance of metobolic syndrome in overweight and obese patients with schizophrenia or schizoaffective disorder: analysis of a mutlicenter, rater-blinded, open-label study. Clin Ther 2005;27:1930–41
   PubMed Web of Science ®Google Scholar
• Takahashi H, Yoshida K, Ishigooka J, Higuchi H. Switching to risperidone after unsuccessful treatment of olanzapine in the first episode of schizophrenia: an open trial. Prog Neuro-Psychopharmacol Biol Psychiatry 2006;30:1067–72
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Prog Neuropsycho-pharmacol Biol Psychiatry 2007;31:1504–9
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Leslie DL, Busch S, et al. Rethinking antipsychotic formulary policy. Schizophr Bull 2008;34:375–80
   PubMed Web of Science ®Google Scholar
• Soumerai SB, Zhang F, Ross-Degnan D, et al. Discontinuities in atypical antipsychotic therapy following a prior authorization and step therapy policy among Medicaid beneficiaries with schizophrenia. Health Affairs, in press
   Google Scholar
• Takahashi H, Kamata M, Yoshida K, et al. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. J Clin Psychiatry 2006;67:1577–82
   PubMed Web of Science ®Google Scholar
• Zhao Z, Namjoshi M, Barber BL, et al. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. CNS Drugs 2004;18:157–64
   PubMed Web of Science ®Google Scholar
• Suzuki T, Uchida H, Watanabe K, et al. How effective is it to sequentially switch among olanzapine, quetiapine and risperidone? A randomized open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berl) 2007;195:285–95
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611–22
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600–10
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164:415–27
   PubMed Web of Science ®Google Scholar
• Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090–5
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799–812
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76
   Google Scholar
• Roy-Byrne PP, Sherbourne CD, Craske MG, et al. Moving treatment research from clinical trials to the real world. Psychiatr Serv 2003;54:327–32
   Google Scholar
• Tunis SL, Johnstone BM, Kinon BJ, et al. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies. Value Health 2000;3:232–42
   PubMedGoogle Scholar
• Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. Special Communication. JAMA 2003;290:1624–32
   Google Scholar
• Lehman AF. A quality of life interview for the chronically mentally ill. EvalProgram Plann 1988;11:51–62
   Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441–9
   PubMed Web of Science ®Google Scholar
• Nyhuis A, Stensland M, Faries D. Responder days for cost effectiveness analyses. Schizophr Res 2003; 60:341
   Google Scholar
• SAS/STAT User’s Guide, Version 8, Cary, NC: SAS Institute Inc., 1999, 3884 pp
   Google Scholar